Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18515
Country/Region: Kenya
Year: 2018
Main Partner: Eastern Deanery AIDS Relief Program
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: HHS/CDC
Total Funding: $5,737,135 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $271,263
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $1,004,916
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,047,448
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $293,973
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $2,949,995
Treatment: Pediatric Treatment (PDTX) $169,540
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 15
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 15
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 15
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 15
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 43
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 44
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 14
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 15
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 146
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 148
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 15
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 204
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 207
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 15
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 45
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 44
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 15
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 43
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 43
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 15
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 43
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 43
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 15
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 43
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 43
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 15
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 16
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 16
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 15
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2019 15
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 179
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 732
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 731
GEND_GBV Number of people receiving post-GBV care 2019 1,463
HTS_SELF 2019 1,060
HTS_SELF 15-19, Female, Directly-Assisted 2019 57
HTS_SELF 15-19, Female, Unassisted 2019 57
HTS_SELF 15-19, Male, Directly-Assisted 2019 19
HTS_SELF 15-19, Male, Unassisted 2019 19
HTS_SELF 20-24, Female, Directly-Assisted 2019 57
HTS_SELF 20-24, Female, Unassisted 2019 57
HTS_SELF 20-24, Male, Directly-Assisted 2019 19
HTS_SELF 20-24, Male, Unassisted 2019 19
HTS_SELF 25-29, Female, Directly-Assisted 2019 57
HTS_SELF 25-29, Female, Unassisted 2019 57
HTS_SELF 25-29, Male, Directly-Assisted 2019 19
HTS_SELF 25-29, Male, Unassisted 2019 19
HTS_SELF 30-34, Female, Directly-Assisted 2019 57
HTS_SELF 30-34, Female, Unassisted 2019 57
HTS_SELF 30-34, Male, Directly-Assisted 2019 19
HTS_SELF 30-34, Male, Unassisted 2019 19
HTS_SELF 35-39, Female, Directly-Assisted 2019 57
HTS_SELF 35-39, Female, Unassisted 2019 57
HTS_SELF 35-39, Male, Directly-Assisted 2019 19
HTS_SELF 35-39, Male, Unassisted 2019 19
HTS_SELF 40-49, Female, Directly-Assisted 2019 57
HTS_SELF 40-49, Female, Unassisted 2019 57
HTS_SELF 40-49, Male, Directly-Assisted 2019 19
HTS_SELF 40-49, Male, Unassisted 2019 19
HTS_SELF 50+, Female, Directly-Assisted 2019 57
HTS_SELF 50+, Female, Unassisted 2019 57
HTS_SELF 50+, Male, Directly-Assisted 2019 19
HTS_SELF 50+, Male, Unassisted 2019 19
HTS_SELF Directly-Assisted 2019 530
HTS_SELF FSW, Directly-Assisted 2019 710
HTS_SELF MSM, Directly-Assisted 2019 159
HTS_SELF PWID, Directly-Assisted 2019 64
HTS_SELF Unassisted 2019 530
HTS_SELF Unassisted - Other 2019 53
HTS_SELF Unassisted - Self 2019 265
HTS_SELF Unassisted - Sex Partner 2019 212
HTS_TST 25-29, Female, Negative 2019 82
HTS_TST 25-29, Female, Negative 2019 153
HTS_TST 25-29, Female, Negative 2019 2,127
HTS_TST 25-29, Female, Negative 2019 38
HTS_TST 25-29, Female, Negative 2019 1,804
HTS_TST 25-29, Male, Negative 2019 170
HTS_TST 25-29, Male, Negative 2019 316
HTS_TST 25-29, Male, Negative 2019 48
HTS_TST 25-29, Male, Negative 2019 3,783
HTS_TST 25-29, Male, Negative 2019 2,664
HTS_TST 30-34, Female, Negative 2019 93
HTS_TST 30-34, Female, Negative 2019 175
HTS_TST 30-34, Female, Negative 2019 2,127
HTS_TST 30-34, Female, Negative 2019 32
HTS_TST 30-34, Female, Negative 2019 2,061
HTS_TST 30-34, Male, Negative 2019 204
HTS_TST 30-34, Male, Negative 2019 382
HTS_TST 30-34, Male, Negative 2019 54
HTS_TST 30-34, Male, Negative 2019 4,538
HTS_TST 35-39, Female, Negative 2019 24
HTS_TST 35-39, Female, Negative 2019 43
HTS_TST 35-39, Female, Negative 2019 2,127
HTS_TST 35-39, Female, Negative 2019 43
HTS_TST 35-39, Female, Negative 2019 515
HTS_TST 35-39, Male, Negative 2019 204
HTS_TST 35-39, Male, Negative 2019 382
HTS_TST 35-39, Male, Negative 2019 72
HTS_TST 35-39, Male, Negative 2019 4,538
HTS_TST 40-49, Female, Negative 2019 24
HTS_TST 40-49, Female, Negative 2019 43
HTS_TST 40-49, Female, Negative 2019 2,127
HTS_TST 40-49, Female, Negative 2019 32
HTS_TST 40-49, Female, Negative 2019 515
HTS_TST 40-49, Male, Negative 2019 66
HTS_TST 40-49, Male, Negative 2019 126
HTS_TST 40-49, Male, Negative 2019 70
HTS_TST 40-49, Male, Negative 2019 1,512
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 122,646
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 10
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 1,159
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 5,165
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 234
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 632
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 152
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 126
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 390
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 186
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 1,344
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 1,310
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 12
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 34
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 89
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 21
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 19
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 540
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 542
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 2,523
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 1,117
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 22
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 64
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 1,520
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 22
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 29
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 26
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 38
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 47
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 39
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 50
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 32
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 56
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 231
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 627
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 150
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 126
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 8,705
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 4,146
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 29,977
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 13,261
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 258
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 755
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 2,665
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 3,993
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 3,993
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 32
HTS_TST_POS 25-29, Female, Positive 2019 17
HTS_TST_POS 25-29, Female, Positive 2019 349
HTS_TST_POS 25-29, Female, Positive 2019 7
HTS_TST_POS 25-29, Female, Positive 2019 31
HTS_TST_POS 25-29, Male, Positive 2019 31
HTS_TST_POS 25-29, Male, Positive 2019 4
HTS_TST_POS 25-29, Male, Positive 2019 12
HTS_TST_POS 25-29, Male, Positive 2019 65
HTS_TST_POS 25-29, Male, Positive 2019 20
HTS_TST_POS 30-34, Female, Positive 2019 17
HTS_TST_POS 30-34, Female, Positive 2019 6
HTS_TST_POS 30-34, Female, Positive 2019 38
HTS_TST_POS 30-34, Male, Positive 2019 38
HTS_TST_POS 30-34, Male, Positive 2019 5
HTS_TST_POS 30-34, Male, Positive 2019 13
HTS_TST_POS 30-34, Male, Positive 2019 79
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 8
HTS_TST_POS 35-39, Female, Positive 2019 9
HTS_TST_POS 35-39, Male, Positive 2019 38
HTS_TST_POS 35-39, Male, Positive 2019 5
HTS_TST_POS 35-39, Male, Positive 2019 15
HTS_TST_POS 35-39, Male, Positive 2019 79
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 6
HTS_TST_POS 40-49, Female, Positive 2019 9
HTS_TST_POS 40-49, Male, Positive 2019 14
HTS_TST_POS 40-49, Male, Positive 2019 13
HTS_TST_POS 40-49, Male, Positive 2019 26
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 166
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 72
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 36
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 240
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 119
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 45
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 153
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 75
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 526
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 233
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) VMMC: 10-14, Positive 2019 20
HTS_TST_POS Service Delivery Point (Facility) VMMC: 15-19, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) VMMC: 20-24, Positive 2019 30
PMTCT_ART Already on ART at beginning of current pregnancy 2019 1,489
PMTCT_ART New on ART 2019 511
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 2,000
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 16,741
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 70
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 70
PMTCT_EID Sum of Infant Age disaggregates 2019 70
PMTCT_STAT 25-29, Female 2019 2,477
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 307
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 2,095
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 75
PMTCT_STAT 30-34, Female 2019 2,514
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 307
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 2,132
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 75
PMTCT_STAT 35-39, Female 2019 2,477
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 307
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 2,095
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 75
PMTCT_STAT 40-49, Female 2019 2,477
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 307
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 2,095
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 75
PMTCT_STAT By Age (Numerator): 10-14 2019 10
PMTCT_STAT By Age (Numerator): 15-19 2019 1,230
PMTCT_STAT By Age (Numerator): 20-24 2019 5,555
PMTCT_STAT By Age (Numerator): 50+ 2019 1
PMTCT_STAT By Number of known positives: 15-19 2019 47
PMTCT_STAT By Number of known positives: 20-24 2019 278
PMTCT_STAT By Number of new negative: 10-14 2019 10
PMTCT_STAT By Number of new negative: 15-19 2019 1,143
PMTCT_STAT By Number of new negative: 20-24 2019 5,089
PMTCT_STAT By Number of new negative: 50+ 2019 1
PMTCT_STAT By Number of new positives: 15-19 2019 40
PMTCT_STAT By Number of new positives: 20-24 2019 188
PMTCT_STAT Number of new ANC and L&D clients 2019 17,273
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 16,741
PMTCT_STAT_den 25-29, Female 2019 2,484
PMTCT_STAT_den 30-34, Female 2019 2,678
PMTCT_STAT_den 35-39, Female 2019 2,484
PMTCT_STAT_den 40-49, Female 2019 2,484
PMTCT_STAT_den By Age (Denominator): <15-19 2019 1,423
PMTCT_STAT_den By Age (Denominator): 10-14 2019 10
PMTCT_STAT_den By Age (Denominator): 20-24 2019 5,709
PMTCT_STAT_den By Age (Denominator): 50+ 2019 1
PrEP_NEW 25-29, Female 2019 38
PrEP_NEW 25-29, Male 2019 16
PrEP_NEW 30-34, Female 2019 26
PrEP_NEW 30-34, Male 2019 21
PrEP_NEW 35-39, Female 2019 26
PrEP_NEW 35-39, Male 2019 21
PrEP_NEW 40-49, Female 2019 26
PrEP_NEW 40-49, Male 2019 16
PrEP_NEW Female 15-19 2019 63
PrEP_NEW Female 20-24 2019 215
PrEP_NEW Female 50+ 2019 10
PrEP_NEW FSW 2019 73
PrEP_NEW Male 15-19 2019 6
PrEP_NEW Male 20-24 2019 31
PrEP_NEW Male 50+ 2019 10
PrEP_NEW MSM 2019 37
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 525
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 278
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 351
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 629
TB_PREV By Age/Sex (Numerator): <15, Female 2019 48
TB_PREV By Age/Sex (Numerator): <15, Male 2019 57
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 889
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 504
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 1,499
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 1,985
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 72
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 72
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 1,175
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 667
TB_PREV_den IPT, Life-long ART, New, Positive 2019 1,984
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 50
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 584
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 60
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 875
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 1,569
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 1,578
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 57
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 584
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 61
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 876
TX_CURR 25-29, Female, Positive 2019 5,032
TX_CURR 25-29, Male, Positive 2019 1,569
TX_CURR 30-34, Female, Positive 2019 3,823
TX_CURR 30-34, Male, Positive 2019 2,451
TX_CURR 35-39, Female, Positive 2019 3,820
TX_CURR 35-39, Male, Positive 2019 2,451
TX_CURR 40-49, Female, Positive 2019 2,604
TX_CURR 40-49, Male, Positive 2019 2,451
TX_CURR Age/Sex: <1 2019 24
TX_CURR Age/Sex: <1-9 2019 706
TX_CURR Age/Sex: 10-14 Female 2019 379
TX_CURR Age/Sex: 10-14 Male 2019 355
TX_CURR Age/Sex: 15-19 Female 2019 801
TX_CURR Age/Sex: 15-19 Male 2019 430
TX_CURR Age/Sex: 20-24 Female 2019 2,232
TX_CURR Age/Sex: 20-24 Male 2019 578
TX_CURR Age/Sex: 50+ Female 2019 2,085
TX_CURR Age/Sex: 50+ Male 2019 883
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 32,674
TX_CURR Sum of age/sex disaggregates 2019 1,231
TX_NEW 25-29, Female, Positive 2019 89
TX_NEW 25-29, Male, Positive 2019 186
TX_NEW 30-34, Female, Positive 2019 102
TX_NEW 30-34, Male, Positive 2019 222
TX_NEW 35-39, Female, Positive 2019 24
TX_NEW 35-39, Male, Positive 2019 222
TX_NEW 40-49, Female, Positive 2019 24
TX_NEW 40-49, Male, Positive 2019 75
TX_NEW Breastfeeding status 2019 32
TX_NEW By Age/Sex: <1 2019 48
TX_NEW By Age/Sex: 1-9 2019 26
TX_NEW By Age/Sex: 10-14 Female 2019 2
TX_NEW By Age/Sex: 10-14 Male 2019 4
TX_NEW By Age/Sex: 15-19 Female 2019 427
TX_NEW By Age/Sex: 15-19 Male 2019 203
TX_NEW By Age/Sex: 20-24 Female 2019 1,474
TX_NEW By Age/Sex: 20-24 Male 2019 654
TX_NEW By Age/Sex: 50+ Female 2019 15
TX_NEW By Age/Sex: 50+ Male 2019 38
TX_NEW FSW 2019 89
TX_NEW MSM 2019 40
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 3,835
TX_NEW People in prisons and other enclosed settings 2019 22
TX_NEW Pregnancy status 2019 458
TX_NEW Sum of Age/Sex disaggregates 2019 2,817
TX_NEW TG 2019 8
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 34,448
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 732
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 53
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 707
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 53
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 19,994
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 1,506
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 10,604
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 799
TX_PVLS_den Denominator: Indication: Routine 2019 32,037
TX_PVLS_den Denominator: Indication: Targeted 2019 2,411
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 62
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 66
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 3,433
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,552
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 6,113
TX_RET Numerator by Status: Breastfeeding 2019 116
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 7,051
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 73
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 77
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 3,958
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2,943
TX_RET_den Denominator by Status: Breastfeeding 2019 133
TX_RET_den Denominator by Status: Pregnant 2019 592
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 32,586
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 745
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 719
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 20,336
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 10,786
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 706
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 322
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 1,065
VMMC_CIRC By Age: 10-14 2019 13,066
VMMC_CIRC By Age: 15-19 2019 6,683
VMMC_CIRC By Age: 20-24 2019 1,128
VMMC_CIRC By Age: 25-29 2019 924
VMMC_CIRC By Age: 50+ 2019 35
VMMC_CIRC By circumcision technique: Device-based VMMC 2019 494
VMMC_CIRC By circumcision technique: Surgical VMMC 2019 21,345
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2019 21,836
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2019 21,836
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2019 20,912
Cross Cutting Budget Categories and Known Amounts Total: $965,420
Key Populations: MSM and TG $30,937
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: Sex Workers $72,238
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Gender: Gender Based Violence (GBV) $89,149
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Human Resources for Health $689,796
Motor Vehicles: Purchased $58,100
Renovation $25,200